Home › Trial NCT07191730
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
- Trial IDNCT07191730
- StatusRecruiting
- PhaseN/A
- Study typeObservational
- SponsorUniversity Hospital, Caen
- Enrollment600
- Start date2025-10-29
- ConditionsCardiotoxicity · Heart Failure · Neoplasms · Breast Neoplasms
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.